with chemotherapy-sensitive disease where 35-50% achieve complete responses (CR) and 15-20% survive progression-free 3-5 years after treatment. [1][2][3][4] [5] [6] [7] [8] TreatmentThe purpose of this study was to determine the outcome of patients with metastatic breast cancer treated with related mortality (TRM) was low with the primary reason for poor outcome of patients receiving HDC being relapse, high-dose busulfan (Bu), melphalan (Mel) and thiotepa (TT) followed by peripheral blood stem cell (PBSC) demonstrating the need for more effective regimens. A regimen of busulfan (Bu), melphalan (Mel) and infusion. Fifty-one patients with chemotherapy refractory (n ‫؍‬ 32) or responsive (n ‫؍‬ 19) metastatic breast thiotepa (TT) was developed in a phase I trial. These drugs have marrow ablation as their dose-limiting toxicity, cancer received Bu (12 mg/kg), Mel (100 mg/m 2 ) and TT (500 mg/m 2 ) followed by PBSC collected after chemoallowing significant dose escalation with the infusion of autologous hematopoietic stem cells. 9 Each of these drugs therapy and growth factor (n ‫؍‬ 43) or growth factor alone (n ‫؍‬ 8). The 100 day treatment-related mortality exhibits significant anti-tumor activity in patients with breast cancer either alone or in combination with other was 8% including one death from cytomegalovirus pneumonia, one from aspiration pneumonia and two alkylating agents. 2,3,[10][11][12] The maximum-tolerated dose (MTD) of TT that could be added to fixed doses of from regimen-related toxicity (RRT). Seven of 28 refractory (25%) and 5/7 (71%) responsive patients 12 mg/kg of Bu and 100 mg/m 2 of Mel was 500 mg/m 2 .
Summary:
with chemotherapy-sensitive disease where 35-50% achieve complete responses (CR) and 15-20% survive progression-free 3-5 years after treatment. [1] [2] [3] [4] [5] [6] [7] [8] TreatmentThe purpose of this study was to determine the outcome of patients with metastatic breast cancer treated with related mortality (TRM) was low with the primary reason for poor outcome of patients receiving HDC being relapse, high-dose busulfan (Bu), melphalan (Mel) and thiotepa (TT) followed by peripheral blood stem cell (PBSC) demonstrating the need for more effective regimens. A regimen of busulfan (Bu), melphalan (Mel) and infusion. Fifty-one patients with chemotherapy refractory (n ‫؍‬ 32) or responsive (n ‫؍‬ 19) metastatic breast thiotepa (TT) was developed in a phase I trial. These drugs have marrow ablation as their dose-limiting toxicity, cancer received Bu (12 mg/kg), Mel (100 mg/m 2 ) and TT (500 mg/m 2 ) followed by PBSC collected after chemoallowing significant dose escalation with the infusion of autologous hematopoietic stem cells. 9 Each of these drugs therapy and growth factor (n ‫؍‬ 43) or growth factor alone (n ‫؍‬ 8). The 100 day treatment-related mortality exhibits significant anti-tumor activity in patients with breast cancer either alone or in combination with other was 8% including one death from cytomegalovirus pneumonia, one from aspiration pneumonia and two alkylating agents. 2, 3, [10] [11] [12] The maximum-tolerated dose (MTD) of TT that could be added to fixed doses of from regimen-related toxicity (RRT). Seven of 28 refractory (25%) and 5/7 (71%) responsive patients 12 mg/kg of Bu and 100 mg/m 2 of Mel was 500 mg/m 2 .
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In a phase I-II trial of Bu/Mel/TT treatment-related with evaluable disease achieved a complete response of all measurable disease or all soft tissue disease with at mortality was 4% among 25 patients with metastatic breast cancer. 13 The purpose of this study was to determine the least improvement in bone lesions (PR*). Fifteen of 51 patients (29%) are alive and progression-free a median outcome for patients with metastatic breast cancer treated with a fixed dose of Bu/Mel/TT and peripheral blood stem of 423 days (range 353-934) after treatment, 5/32 (16%) with refractory disease and 10/19 (53%) with responsive cell (PBSC) infusion. disease. The probabilities of progression-free survival (PFS) at 1.5 years for the patients with refractory (n ‫؍‬ 32) and responsive (n ‫؍‬ 19) disease were 0.24 and 0.53, Patients and methods respectively. These preliminary data suggest that highdose Bu/Mel/TT has significant activity in patients with advanced breast cancer and may be superior to some
Between May 1993 and 15 June 1995, 51 women with refractory (n ϭ 32) or responsive (n ϭ 19) stage IV breast previously published regimens. Keywords: busulfan; melphalan; thiotepa; PBSC; breast cancer were treated with high-dose Bu/Mel/TT followed by PBSC infusion (Table 1) . Patients were eligible for study cancer if they had a bilirubin Ͻ2 mg/dl, a creatinine clearance Ͼ50 ml/min and a Karnofsky score of у70. Patients with active or untreated CNS disease were excluded. TwentyThere have been many reports of clinical trials evaluating eight patients were treated at the Fred Hutchinson Cancer high-dose chemotherapy (HDC) and autologous stem cell Research Center (FHCRC) or a separate but affiliated acasupport in women with advanced stage IV breast cancer.
demic center (University of Washington, Oregon Health Although these trials have reported high response rates, 50-Sciences University) and 23 were treated at one of seven 70% of patients who achieve complete responses will participating community cancer centers listed in the Appenrelapse. eved complete response after HDC with PBSC infusion received chest wall radiation and five received local radiation therapy to areas of bone metastasis.
Collection, cryopreservation and infusion of PBSC Regimen-related toxicity grading
Peripheral blood stem cells were collected after the adminRegimen-related toxicity (RRT) was graded to day 100 istration of recombinant granulocyte colony-stimulating after PBSC infusion using a previously described system factor (G-CSF) alone (n ϭ 8), 14 after intermediate-dose to assess toxicities to the oral, renal, hepatic, cardiac, pulchemotherapy and G-CSF or recombinant granulocytemonary, gastrointestinal (GI), bladder, skin and central nermacrophage colony-stimulating factor (GM-CSF) (n ϭ 40) vous systems. 13, 20 Infection was excluded from this grading or after conventional doxorubicin-based chemotherapy and system. Veno-occlusive disease (VOD) of the liver was G-CSF (n ϭ 3). Intermediate-dose chemotherapy for 40 defined as liver toxicity secondary to HDC. VOD was patients consisted of cyclophosphamide 4 g/m 2 (n ϭ 8), , etoposide cells of the terminal hepatic venules, dilatation of the sinus-600 mg/m 2 and cisplatin 105 mg/m 2 (CEP) (n ϭ 15) 18 or oids and necrosis of hepatocytes. 21 Idiopathic pneumonia taxol 250 mg/m 2 (n ϭ 1). The techniques of PBSC cryopresyndrome (IPS) was defined as pulmonary infiltrates not servation, thawing and reinfusion have been reported. 14, 19 associated with pulmonary edema or an identifiable infecThe day of PBSC infusion was designated day 0.
tious cause.
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Second courses and intermediate-dose chemotherapy Evaluation of response
Patients were considered to have refractory disease if they Thirteen patients received a second course of intermediatedose chemotherapy with cyclophosphamide, etoposide, and did not achieve a partial remission (PR) or progressed following initial chemotherapy for stage IV disease. Patients cisplatin (n ϭ 8), cyclophosphamide and taxol (n ϭ 3), who achieved a 50% reduction in the spread of all measurable metastatic disease (PR) or complete response (CR) following initial chemotherapy for metastatic disease or who were rendered disease-free following surgery or radiation therapy without receiving chemotherapy were classified as having responsive disease. Bone-only disease was categorized as responsive if sclerosis of prior lesions was demonstrated with no new lesions and normalization of a tumor marker following initial chemotherapy occurred. Patients who entered HDC without measurable disease were classified as having no evidence of disease (NED). De novo ease included ipsilateral or contralateral nodal, chest wall or breast recurrences. Visceral disease was defined as liver, lung or abdominal metastases. Baseline staging was carried out within 10 weeks of HDC using imaging studies (CT or MRI scans of brain, chest, abdomen and pelvis and radionuclide bone scans or skeletal MRIs), tumor markers (CA 15-3, CA 27-29, CEA or CA 125) and bilateral bone marrow biopsies. Patients had tumor markers repeated within 6 weeks of HDC and those with measurable visceral or soft tissue disease were restaged by CT or MRI scans at previous sites of disease. All patients were restaged at 60-80 days, at 6 months and yearly after HDC. disappearance of all tumor for greater than 30 days, and PR if there was a reduction of 50% or more in the size of measurable disease for at least 30 days. Responses of less 1) or chemotherapy (n ϭ 7) prior to entry on to the study. All 11 patients with bone-only disease had failed horthan PR or progressive disease were considered no response (NR). Patients with measurable disease and bone metastasis monal therapy. or bone-only disease were defined as PR* if there was a CR of measurable disease in non-bone areas and sclerosis
Intermediate-dose chemotherapy of prior lytic bone lesions but continuing activity by bone scan in areas of prior uptake without the development of Thirty-three patients received one course and 13 patients received two courses of intermediate-dose therapy before new bone lesions. 6 Actuarial probabilities were calculated from day 0 using the method of Kaplan and Meier. 23 End-HDC and PBSC infusion. There were no grade 3-4 RRT following intermediate-dose chemotherapy. points for survival were duration from PBSC infusion until death censored by the date of last contact. The endpoints for progression-free survival (PFS) were death and relapse
High-dose chemotherapy with Bu/Mel/TT and PBSC or progression censored by the date of last contact. infusion
All patients received the prescribed doses of Bu, Mel, TT.
Results
Peripheral blood stem cell infusion and hematologic Patient characteristics recovery
The median number of CD34 + cells infused was 8.20 ϫ Table 1 shows the characteristics of the 51 patients treated.
Eleven patients (seven with refractory and four with 10 6 CD34 ϩ cells/kg (range 2.56-59.09). One patient died on day 6 before recovery of neutrophils or platelets. The responsive disease) presented with de novo metastatic disease. Forty-three patients received a median of one convenremaining 50 patients achieved an ANC Ͼ0.5 ϫ 10 9 /l at a median of 10 days (range 8-14) and a platelet level Ͼ20 tional chemotherapy regimen (range 1-3) for stage IV disease. The eight patients who had not received conventional ϫ 10 9 /l at a median of 11 days (range 1-26) after infusion of PBSC. chemotherapy for stage IV disease were given one cycle of intermediate-dose chemotherapy for mobilization (n ϭ 6) or two cycles for mobilization and debulking (n ϭ 2). All Treatment-related morbidity and mortality (Table 2 ) eight were classified as chemotherapy sensitive. Twelve patients, 10 with responsive and two with refractory disease There were six episodes of grade III/IV RRT occurring in six (12%) patients. Four patients experienced grade III tox-(24%) were rendered NED by surgery (n ϭ 4), RT (n ϭ Table 2 Regimen-related toxicity (n ϭ 51) icities (two gastrointestinal, one VOD and one hemorrhagic chemotherapy were 0.33 and 0.38, respectively. The probabilities of survival and PFS at 1.5 years for the 13 patients cystitis). Two patients (4%) died of RRT within 100 days of treatment. One died from IPS at 100 days post-HDC and (10 with refractory and three with responsive disease) who received two courses of intermediate-dose therapy were one patient with a pre-treatment history of acute pulmonary edema and a decreased left ventricular ejection fraction of 0.21 and 0.27, respectively. 40% developed an acute arrythmia and died from cardiac arrest on day 16. One patient died from CMV pneumonia
Outcome for refractory patients on day 100 and one patient with vomiting died from aspiration pneumonia on day 6. Thus, a total of four patients Among 32 patients with refractory disease, two were NED pre-HDC and two died before day 100 from treatment-(8%) died from complications of HDC with a 100 day nonrelapse mortality of 0.06. related complications. Thus, 28 were evaluable for response. Seven of 28 (25%) achieved a CR/PR* and four There were four episodes of non-fatal bacteremia secondary to Staphylococcus epidermidis, one non-fatal candidal (14%) are alive progression-free. One of two patients who were NED remains progression-free at 353 days. Sites of pneumonia, one CMV gastritis and one fatal CMV pneumonia at 100 days.
disease involvement for the five survivors (16%) with refractory disease included: bone-only (n ϭ 2); lung (n ϭ One of 13 patients who received two courses of intermediate-dose chemotherapy, 2/33 who received one and 1/6
2) and local (n ϭ 1). The probabilities of survival and PFS for the 32 patients with refractory disease at 1.5 years were who did not receive any intermediate-dose chemotherapy prior to HDC died of TRM.
0.25 and 0.24, respectively ( Figure 1 ).
Outcome for responsive patients Response and survival (Table 3)
Of 51 patients, 12 were NED pre-HDC and four died before Nineteen patients were defined as having responsive disease. Nine of these patients had measurable disease, of day 100 from treatment-related complications, leaving 35 patients evaluable for response. Twelve of 35 (34%) achiwhom five achieved a PR*. Overall, 10 of the 19 (53%) (four in PR* and six NED) are alive and progression-free eved a CR/PR* (five with responsive and seven with refractory disease) of whom eight are alive and progression-free a median of 612 (range 364-934) days after HDC. The probabilities of survival and PFS at 1.5 years for patients a median of 589 days (range 339-771) after HDC. Seven of the 12 patients (24%) who were NED (10 with responwith responsive disease were 0.53 and 0.53, respectively ( Figure 2 ). One patient with responsive disease in PR* died sive and two with refractory disease) remain progressionfree a median of 367 days (range 353-934) after HDC.
from suicide 440 days after PBSC infusion. Thus, 15 patients (29%) are alive without progression with a median follow-up of 423 days (range 339-934). Survival and PFS for all 51 patients at 1.5 years was 0.26 and 0.24, Discussion respectively. PFS at 1.5 years for the 24 patients who were NED or achieved CR/PR* post-HDC was 0.64.
A regimen of high-dose Bu/Mel/TT followed by PBSC infusion in patients with metastatic breast cancer was assoFour of 22 patients (one CR and three NED) who had failed doxorubicin as adjuvant therapy, and two with more ciated with an 8% 100 day treatment-related mortality. Death occurred in 2/32 patients with refractory disease and than one site of metastatic involvement are alive and progression-free a median of 581 days (range 364-687) after 2/19 with responsive disease. The major non-hematologic morbidity was gastrointestinal with all patients developing HDC.
The probabilities of survival and PFS at 1.5 years for significant stomatitis with grade III gastroenteritis occurring in two patients. the 33 patients (21 with refractory and 12 with responsive disease) who received one course of intermediate-dose
Response rates were high with CR/PR* and PR rates of 1187 Table 3 Response and outcome (n ϭ 51) 24 For patients who have failed chemotherapy, CR therapy mobilization of PBSC, and HDC with cyclophosphamide, TT and carboplatin revealed that the presence of rates as high as 48% have been reported but the median time to progression has been 6-10 months with few or no liver or lung metastasis or a history of receiving doxorubicin as adjuvant therapy were adverse risk factors with no survivors. [1] [2] [3] 5, 11, 24 In the current study, five patients (16%) with refractory disease are surviving progression-free with patient surviving progression-free with any one of these factors.
8 a minimum follow-up of 1 year. These results justify further attempts to develop new HDC treatment regimens In the current study, there were four patients with lung involvement, two with more than one site of disease and or strategies for patients with refractory breast cancer.
When HDC was administered to patients with stage IV four who failed adjuvant doxorubicin who are surviving progression-free. Although numbers are small, these results breast cancer who were responding to initial induction therapy, other studies have reported CR rates of 30-60% with suggest that further evaluation of the Bu/Mel/TT regimen should be carried out in patients with adverse risk factors. 10-25% of patients remaining in CR for more than 2 years.
12, 25 In the present study, 10/19 patients (53%) with Intermediate-dose chemotherapy given for mobilization of PBSC and/or for tumor reduction prior to HDC may responsive disease are surviving without progression a median of 612 days. In a recent review of the literature, 20 have improved the outcome for some patients. 
